01 · RESISTANCE TARGET DISCOVERY
Find mechanisms of resistance to KRAS G12C inhibitors.
Example question: “What targets and pathways are most strongly implicated in acquired resistance to KRAS G12C inhibition in NSCLC?” Scout can assemble published resistance mechanisms, genes, pathway evidence, expression findings, and supporting citations into ranked hypotheses for follow-up.
Resistance mechanismsTarget hypothesesEvidence rankingCitations
02 · TARGET VALIDATION
Pressure-test a new oncology target before advancing it.
Example question: “Build the case for and against inhibiting this target in pancreatic cancer.” Scout can investigate disease association, genetics, expression, pathway biology, published perturbation evidence, known liabilities, and contradictory findings — then show where the hypothesis is strong and where evidence is missing.
Pro / con evidenceBiological rationaleEvidence gapsNext experiments
03 · INDICATION EXPANSION
Find new indications for an existing asset.
Example question: “Given this molecule’s mechanism and target profile, what additional disease indications have the strongest biological rationale?” Scout can connect mechanism of action to disease pathways, genetic associations, published evidence, related clinical activity, and competitive programs to prioritize expansion hypotheses.
Indication rankingMechanistic rationaleClinical contextCompetitive activity
04 · HIT / LEAD PRIORITIZATION
Choose which compounds move into experimental testing.
Example question: “Rank these 40 compounds for progression based on potency, selectivity, predicted ADMET, structural fit, and known liabilities.” Scout can coordinate the required analyses, compare candidates against the same criteria, and produce an evidence-backed shortlist for scientist review.
Ranked compoundsADMETStructural evidenceLiability flags
05 · EARLY LIABILITY ASSESSMENT
Identify why a promising molecule could fail later.
Example question: “What developability risks should we investigate before advancing this lead series?” Scout can evaluate predicted ADME, toxicity, physicochemical properties, off-target concerns, and literature-reported liabilities to surface risks before additional wet-lab investment.
Risk profileToxicity signalsADMEFollow-up tests
06 · RESPONSE BIOMARKER DISCOVERY
Find biomarkers that may explain treatment response.
Example question: “Which biomarkers could distinguish responders from non-responders for this mechanism?” Scout can investigate gene and protein expression, pathway context, disease subtypes, published response associations, and mechanistic evidence to generate biomarker hypotheses for validation.
Biomarker hypothesesExpression evidenceMechanismValidation rationale
07 · COMPETITIVE SCIENTIFIC LANDSCAPE
Map who is pursuing a target — and how.
Example question: “Who is developing therapies against this target, which modalities are they using, and where is there scientific whitespace?” Scout can connect companies, assets, mechanisms, publications, and clinical programs to create a research-driven view of the competitive field.
Companies + assetsModalitiesClinical programsWhitespace
08 · SCIENTIFIC DUE DILIGENCE
Evaluate the science behind an external asset.
Example question: “What evidence supports this asset and mechanism, what contradicts it, and what should we investigate before licensing?” Scout can synthesize target biology, mechanism, published studies, clinical evidence, competitive context, and unresolved scientific questions into a cited diligence package.
Evidence packageRed flagsCompetitive contextDiligence questions